Acute Myeloid Leukemia (AML)

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

By

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

By

This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

By

Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.

Novel Therapies Needed to Improve TP53-mutant AML Outcomes

By

Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

Telomere Length Predicts Risk for Delayed Recovery in Pediatric Patients With AML

By

Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

By

Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

Study Evaluates Gemtuzumab Ozogamicin in Older Patients With AML

By

First-line monotherapy with low-dose gemtuzumab ozogamicin significantly improved overall survival compared with best supportive care.

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

Blood Test Could Help Predict Acute Myeloid Leukemia Recurrence

A simple blood test can identify post-chemo patients with the NPM1 gene mutation.

Molecular Signature Predicts Transition from Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Progress from myelodysplastic syndrome to AML is linked to the enzyme glycogen synthase kinase, and a molecular signature is found to predict clinical outcomes of patients with MDS.

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

By

Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

By

Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

By

An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

By

For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

By

Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

By

The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.

Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)

By

More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.

Molecule Inhibits Kinase Pair, Leading to Restored Normal Cell Function in Cancerous Cells

By

A molecule isolated from sea sponges and later synthesized can halt the growth of cancerous cells, opening the door to a new treatment for leukemia.

Social factors may impact survival among young patients with leukemia

By

A new study reveals that insurance status, marital status, and county-level income may affect survival for younger patients with AML, indicating that efforts are needed to address social factors that impact critical aspects of health.

Researchers discover a potential biomarker for AML relapse after stem cell transplant

By

Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.

Genetic mutations identified during remission of leukemia may help predict risk of relapse, survival

By

Even though potentially curative therapy is now available for many patients with AML, the therapy is expensive and is associated with significant side effects. This study explained that identifying patients at high risk for relapse would be helpful clinically.

Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use

Early discharge after intensive AML, MDS chemo can reduce costs, antibiotics use

Early discharge after intensive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) can reduce both costs and use of intravenous antibiotics, according to a new study.

In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative

In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative

Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.

Transitioning High-Dose AML Chemo to Outpatient Setting Improves Quality of Life

Transitioning High-Dose AML Chemo to Outpatient Setting Improves Quality of Life

By

Transitioning a long-standing intensive chemotherapy regimen for acute myeloid leukemia (AML) to the outpatient setting is safe and feasible.

Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia

Antibiotic prophylaxis with contrimoxazole/colistin similar to ciprofloxacin in acute myeloid leukemia

Antibiotic prophylaxis regimen used from cotrimoxazole/colistin (COT/COL) to ciprofloxacin (CIP) in patients with acute myeloid leukemia (AML).

Presence of protein marks toxicity in leukemia

Presence of protein marks toxicity in leukemia

Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).

Oral inhibitor shows clinical activity in poor-prognosis acute myelogenous leukemia (AML)

By

An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.

Study findings show improved survival in aggressive acute myeloid leukemia (AML)

By

Survival rates for patients who relapse in their battle with acute myeloid leukemia may benefit from therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

By

Combined treatment with azacitidine and lenalidomide may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs